MX2022007680A - Nanoparticulas lipidicas para administracion de acidos nucleicos. - Google Patents

Nanoparticulas lipidicas para administracion de acidos nucleicos.

Info

Publication number
MX2022007680A
MX2022007680A MX2022007680A MX2022007680A MX2022007680A MX 2022007680 A MX2022007680 A MX 2022007680A MX 2022007680 A MX2022007680 A MX 2022007680A MX 2022007680 A MX2022007680 A MX 2022007680A MX 2022007680 A MX2022007680 A MX 2022007680A
Authority
MX
Mexico
Prior art keywords
delivery
nucleic acids
lipid nanoparticles
cationic lipids
compositions
Prior art date
Application number
MX2022007680A
Other languages
English (en)
Inventor
Patrick Baumhof
Gemma Navarro
Original Assignee
Curevac Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curevac Ag filed Critical Curevac Ag
Publication of MX2022007680A publication Critical patent/MX2022007680A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invención se refiere a lípidos catiónicos novedosos y a composiciones novedosas que comprenden lípidos catiónicos útiles para la administración de ácidos nucleicos en células vivas.
MX2022007680A 2019-12-20 2020-12-18 Nanoparticulas lipidicas para administracion de acidos nucleicos. MX2022007680A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2019086825 2019-12-20
PCT/EP2020/087254 WO2021123332A1 (en) 2019-12-20 2020-12-18 Lipid nanoparticles for delivery of nucleic acids

Publications (1)

Publication Number Publication Date
MX2022007680A true MX2022007680A (es) 2022-09-26

Family

ID=69156396

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022007680A MX2022007680A (es) 2019-12-20 2020-12-18 Nanoparticulas lipidicas para administracion de acidos nucleicos.

Country Status (11)

Country Link
US (1) US20230090515A1 (es)
EP (1) EP4076647A1 (es)
JP (1) JP2023507465A (es)
KR (1) KR20220121246A (es)
CN (1) CN114901360A (es)
AU (1) AU2020407285A1 (es)
BR (1) BR112022011803A2 (es)
CA (1) CA3162019A1 (es)
IL (1) IL293890A (es)
MX (1) MX2022007680A (es)
WO (1) WO2021123332A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3423595A1 (en) 2016-03-03 2019-01-09 CureVac AG Rna analysis by total hydrolysis
US20240277830A1 (en) 2020-02-04 2024-08-22 CureVac SE Coronavirus vaccine
JP2023527747A (ja) * 2020-05-18 2023-06-30 ジェネレーション バイオ カンパニー 新規脂質及びそれらのナノ粒子組成物
CA3200234A1 (en) 2020-11-25 2022-06-02 Daryl C. Drummond Lipid nanoparticles for delivery of nucleic acids, and related methods of use
KR20230164648A (ko) 2020-12-22 2023-12-04 큐어백 에스이 SARS-CoV-2 변이체에 대한 RNA 백신
CN117940158A (zh) 2021-09-03 2024-04-26 库瑞瓦格欧洲公司 用于核酸递送的包含磷脂酰丝氨酸的新型脂质纳米颗粒
EP4395748A1 (en) 2021-09-03 2024-07-10 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids
CA3237658A1 (en) * 2021-10-08 2023-04-13 Pfizer Inc. Immunogenic lnp compositions and methods thereof
EP4422698A1 (en) 2021-10-29 2024-09-04 CureVac SE Improved circular rna for expressing therapeutic proteins
WO2023076704A1 (en) * 2021-10-31 2023-05-04 CELESTIAL THERAPEUTICS Inc. SELECTIVE AGONISM OF SPECIFIC PATTERN RECOGNITION RECEPTORS IN mRNA CONSTRUCTS FOR SAFE, EFFECTIVE AND DURABLE VACCINES
FR3129833B1 (fr) 2021-12-03 2024-09-06 Univ Claude Bernard Lyon Nanoparticules pour la liberation d’acides nucleiques
CA3242439A1 (en) * 2021-12-17 2023-06-22 Sanofi Lyme disease rna vaccine
CA3242476A1 (en) * 2021-12-17 2023-06-22 Pfizer Inc. Polynucleotide compositions and uses thereof
WO2023121964A1 (en) * 2021-12-20 2023-06-29 Beam Therapeutics Inc. Nanomaterials comprising disulfides
WO2023144330A1 (en) 2022-01-28 2023-08-03 CureVac SE Nucleic acid encoded transcription factor inhibitors
KR102560772B1 (ko) 2022-03-21 2023-07-28 주식회사 메디치바이오 신규한 이온화지질 및 이를 이용한 지질나노입자 조성물
US12064479B2 (en) 2022-05-25 2024-08-20 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
WO2023227608A1 (en) 2022-05-25 2023-11-30 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
EP4342460A1 (en) 2022-09-21 2024-03-27 NovoArc GmbH Lipid nanoparticle with nucleic acid cargo
WO2024089229A1 (en) 2022-10-28 2024-05-02 CureVac SE Improved formulations comprising lipid-based carriers encapsulating rna
US20240156949A1 (en) 2022-10-28 2024-05-16 Glaxosmithkline Biologicals Sa Nucleic Acid Based Vaccine
US20240180844A1 (en) * 2022-11-11 2024-06-06 Calusa Bio, Llc Particle compositions comprising polysarcosine lipid conjugates
CN116712536A (zh) * 2022-11-18 2023-09-08 上海复诺健生物科技有限公司 针对痘病毒的信使核糖核酸疫苗
WO2024134551A1 (en) * 2022-12-23 2024-06-27 Pfizer Inc. Lipid particle compositions and methods of use thereof
WO2024184500A1 (en) 2023-03-08 2024-09-12 CureVac SE Novel lipid nanoparticle formulations for delivery of nucleic acids
CN116617414B (zh) * 2023-03-31 2024-04-05 中国农业大学 一种脂质体及其制备方法和应用
CN116536355B (zh) * 2023-03-31 2023-10-20 中国农业大学 一种crRNA转录载体、CRISPR/Cas13d体系和RNA投送体系和应用
CN116549667B (zh) * 2023-05-29 2024-02-09 四川普锐特药业有限公司 一种pas修饰的脂质纳米粒、包含其的药物制剂，及其制备方法和用途

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1493825A3 (en) 1990-06-11 2005-02-09 Gilead Sciences, Inc. Method for producing nucleic acid ligands
DE59708838D1 (de) 1996-08-30 2003-01-09 Jens Peter Fuerste Spiegelselektion und spiegelevolution von nucleinsäuren
US6958239B2 (en) 1996-11-21 2005-10-25 Oligos Etc Inc. Three component chimeric antisense oligonucleotides
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
EP1818409A1 (en) 1999-09-09 2007-08-15 CureVac GmbH Transfer of mRNAusing polycationic compounds
DK1857122T3 (da) 2001-06-05 2011-03-21 Curevac Gmbh Stabiliseret mRNA med forøget G/C-indhold, kodende for et viralt antigen
US7074596B2 (en) 2002-03-25 2006-07-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthesis and use of anti-reverse mRNA cap analogues
CA2659301A1 (en) 2006-07-28 2008-02-07 Applera Corporation Dinucleotide mrna cap analogs
EP2046954A2 (en) 2006-07-31 2009-04-15 Curevac GmbH NUCLEIC ACID OF FORMULA (I): GIXmGn, OR (II): CIXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT
DE102006061015A1 (de) 2006-12-22 2008-06-26 Curevac Gmbh Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC
CA2692906C (en) 2007-06-19 2016-01-19 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthesis and use of anti-reverse phosphorothioate analogs of the messenger rna cap
CA2709875C (en) 2008-01-02 2019-07-16 Tekmira Pharmaceuticals Corporation Improved compositions and methods for the delivery of nucleic acids
WO2009095226A2 (en) 2008-01-31 2009-08-06 Curevac Gmbh Nucleic acids of formula (i) (nuglxmgnnv)a and derivatives thereof as an immunostimulating agent/adjuvant
PT2279254T (pt) 2008-04-15 2017-09-04 Protiva Biotherapeutics Inc Novas formulações lipídicas para entrega de ácido nucleico
PL215513B1 (pl) 2008-06-06 2013-12-31 Univ Warszawski Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
PL2350043T3 (pl) 2008-10-09 2014-09-30 Tekmira Pharmaceuticals Corp Ulepszone aminolipidy i sposoby dostarczania kwasów nukleinowych
WO2010048536A2 (en) 2008-10-23 2010-04-29 Alnylam Pharmaceuticals, Inc. Processes for preparing lipids
NO2355851T3 (es) 2008-11-10 2018-09-01
EP3243504A1 (en) 2009-01-29 2017-11-15 Arbutus Biopharma Corporation Improved lipid formulation
WO2010129709A1 (en) 2009-05-05 2010-11-11 Alnylam Pharmaceuticals, Inc. Lipid compositions
KR20230098713A (ko) 2009-06-10 2023-07-04 알닐람 파마슈티칼스 인코포레이티드 향상된 지질 조성물
EP2281579A1 (en) 2009-08-05 2011-02-09 BioNTech AG Vaccine composition comprising 5'-Cap modified RNA
CA2800401C (en) 2010-06-03 2020-09-15 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
WO2012016184A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
WO2012019630A1 (en) 2010-08-13 2012-02-16 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
WO2012116715A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in newborns and infants
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
US8969545B2 (en) 2011-10-18 2015-03-03 Life Technologies Corporation Alkynyl-derivatized cap analogs, preparation and uses thereof
UA119028C2 (uk) 2011-10-27 2019-04-25 Массачусеттс Інстітьют Оф Текнолоджі Функціоналізовані на n-кінці амінокислотні похідні, здатні утворювати мікросфери, що інкапсулюють лікарський засіб
CN103930398B (zh) * 2011-11-18 2016-08-24 日油株式会社 具有改进的细胞内动力学的阳离子脂质
WO2013120499A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
CA2866945C (en) 2012-03-27 2021-05-04 Curevac Gmbh Artificial nucleic acid molecules comprising a 5'top utr
BR112016001192A2 (pt) 2013-08-21 2017-08-29 Curevac Ag Vacina contra a raiva
CN111588695A (zh) 2014-06-24 2020-08-28 川斯勒佰尔公司 用于递送核酸的立体化学富集组合物
AU2015355546B2 (en) 2014-12-03 2021-10-14 Agilent Technologies, Inc. Guide RNA with chemical modifications
EP3247363A4 (en) 2015-01-21 2018-10-03 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
US20180085474A1 (en) 2015-01-23 2018-03-29 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
EP3252043B1 (en) * 2015-01-30 2020-09-30 NOF Corporation Cationic lipid
EP3603661A3 (en) 2015-04-22 2020-04-01 CureVac AG Rna containing composition for treatment of tumor diseases
EP3289083A4 (en) 2015-04-27 2018-12-19 The Trustees Of The University Of Pennsylvania Nucleoside-modified rna for inducing an adaptive immune response
US20190054112A1 (en) 2015-09-18 2019-02-21 Moderna Therapeutics, Inc. Polynucleotide formulations for use in the treatment of renal diseases
EP3906789B1 (en) 2015-09-21 2023-11-22 TriLink BioTechnologies, LLC Initiating capped oligonucleotide primers for synthesizing 5'-capped rnas
EP3360576B1 (en) * 2015-10-08 2022-09-28 NOF Corporation O/w type emulsion
WO2017066782A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Hydrophobic mrna cap analogs
ES2914225T3 (es) 2015-10-16 2022-06-08 Modernatx Inc Análogos de cap de ARNm con enlace de fosfato modificado
WO2017066789A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Mrna cap analogs with modified sugar
WO2017066797A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Trinucleotide mrna cap analogs
EP3362460A1 (en) 2015-10-16 2018-08-22 Modernatx, Inc. Mrna cap analogs and methods of mrna capping
WO2017066791A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Sugar substituted mrna cap analogs
WO2017070620A2 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Broad spectrum influenza virus vaccine
AU2016342045A1 (en) 2015-10-22 2018-06-07 Modernatx, Inc. Human cytomegalovirus vaccine
WO2018081480A1 (en) * 2016-10-26 2018-05-03 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
EP3964200A1 (en) 2015-12-10 2022-03-09 ModernaTX, Inc. Compositions and methods for delivery of therapeutic agents
LT3394030T (lt) 2015-12-22 2022-04-11 Modernatx, Inc. Junginiai ir kompozicijos terapinei medžiagai teikti intraceliuliniu būdu
WO2017140905A1 (en) 2016-02-17 2017-08-24 Curevac Ag Zika virus vaccine
WO2017191274A2 (en) 2016-05-04 2017-11-09 Curevac Ag Rna encoding a therapeutic protein
WO2018075827A1 (en) 2016-10-19 2018-04-26 Arcturus Therapeutics, Inc. Trinucleotide mrna cap analogs
IL266194B2 (en) 2016-10-26 2023-09-01 Curevac Ag mRNA vaccines with lipid nanoparticles
EP3808380A1 (en) 2016-12-08 2021-04-21 CureVac AG Rna for treatment or prophylaxis of a liver disease
WO2018126084A1 (en) 2016-12-30 2018-07-05 Phaserx, Inc. Branched peg molecules and related compositions and methods
US11015204B2 (en) 2017-05-31 2021-05-25 Arcturus Therapeutics, Inc. Synthesis and structure of high potency RNA therapeutics
WO2018237369A2 (en) * 2017-06-23 2018-12-27 Vical Incorporated LIPID NANOPARTICLE MEDIA ADMINISTRATION OF PLASMIDIC DNA EXPRESSING CRISPR FOR THE TREATMENT OF CHRONIC INFECTION WITH HEPATITIS B VIRUS
RU2020115287A (ru) 2017-10-19 2021-11-19 Куревак Аг Новые молекулы искусственных нуклеиновых кислот
EP3740241A1 (en) * 2018-01-18 2020-11-25 eTheRNA Immunotherapies NV Lipid nanoparticles
WO2019188867A1 (ja) * 2018-03-27 2019-10-03 日油株式会社 細胞内動態を改善した新規カチオン性脂質
US20210361761A1 (en) * 2018-04-05 2021-11-25 Curevac Ag Novel yellow fever nucleic acid molecules for vaccination
BR112020020933A2 (pt) * 2018-04-17 2021-04-06 Curevac Ag Moléculas de rna de rsv inovadoras e composições para vacinação
CN117430538A (zh) 2018-05-24 2024-01-23 川斯勒佰尔公司 硫酯阳离子脂质
AU2019370563A1 (en) 2018-11-02 2021-05-27 Genevant Science GmbH Therapeutic methods
CA3137450A1 (en) 2019-04-26 2020-10-29 Genevant Sciences Gmbh Lipid nanoparticles

Also Published As

Publication number Publication date
US20230090515A1 (en) 2023-03-23
BR112022011803A2 (pt) 2022-08-30
IL293890A (en) 2022-08-01
CA3162019A1 (en) 2021-06-24
AU2020407285A1 (en) 2022-08-11
KR20220121246A (ko) 2022-08-31
JP2023507465A (ja) 2023-02-22
CN114901360A (zh) 2022-08-12
WO2021123332A1 (en) 2021-06-24
EP4076647A1 (en) 2022-10-26

Similar Documents

Publication Publication Date Title
MX2022007680A (es) Nanoparticulas lipidicas para administracion de acidos nucleicos.
MX2019005287A (es) Lipidos cationicos para suministro de acido nucleico y su preparacion.
MX2021005389A (es) Formulaciones de nanoparticulas lipidicas.
EP4286012A3 (en) Compounds and compositions for intracellular delivery of therapeutic agents
EP4036079A3 (en) Compounds and compositions for intracellular delivery of agents
MX2024000327A (es) Composiciones y metodos para la administracion de arn mensajero.
MX2024001138A (es) Arn guia modificados.
WO2020051220A8 (en) Compositions and methods for organ specific delivery of nucleic acids
IL286515A (en) Novel lipids and nanoparticle formulations of lipids for delivery of nucleic acids
CA2868034C (en) Ionizable cationic lipids
EP4332576A3 (en) Synergistic enhancement of the delivery of nucleic acids via blended formulations
EP4219713A3 (en) Products and compositions
WO2015011633A8 (en) Compositions and methods for delivering messenger rna
MX2022006512A (es) Lipidos cationicos de trialquilo y metodos de uso de los mismos.
MD3386484T2 (ro) Compoziții și metode de livrare a unor agenți terapeutici
WO2016154127A3 (en) Compositions and methods for treating hypertriglyceridemia
BR112014001907A2 (pt) produção de dha e outros lc-pufas em plantas
WO2011149733A3 (en) Novel amino alcohol cationic lipids for oligonucleotide delivery
EP4241767A3 (en) Novel lipids and compositions for the delivery of therapeutics
WO2012170889A8 (en) Cleavable lipids
IL290862A (en) Preparations and methods for administering nucleic acids to cells
MX2012014079A (es) Lipidos biodegradables para la administracion de agentes activos.
MX2011003843A (es) Incorporacion de adyuvante en inmunonanoterapeuticos.
IN2014CN04251A (es)
MX2024002726A (es) Nuevas nanoparticulas lipidicas para la administracion de acidos nucleicos.